Genedrive (GDR) Price & Analysis

Compare

60 Followers

GDR Stock Chart & Stats

0.88 p

0.03 p(1.30%)

At close: Jan 09 4:00 PM EST

0.88 p

0.03 p(1.30%)

Day’s Range― - ―

52-Week Range0.19 p - 2.17 p

Previous CloseN/A

Volume280.42K

Average Volume (3M)49.58M

Market Cap

£16.86M

Enterprise Value5.02M

Total Cash (Recent Filing)£1.18M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-1.49

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,605,568,200

10 Day Avg. Volume14,118,826

30 Day Avg. Volume49,583,488

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)5.48

Price to Sales (P/S)10.31

P/FCF Ratio-1.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Revenue ModelThe business model combines instrument placements with recurring single-use test-kit sales, creating an annuity-like revenue stream as installed bases consume assays. Over 2-6 months this supports predictable unit economics and long-term revenue per device if clinical adoption continues.

Accelerating Revenue GrowthA ~25% uplift in 2025 revenue signals improving commercial traction for a small diagnostic platform. Sustained top-line improvement off a low base implies product-market fit gains and expanding assay uptake, which can compound into durable scale benefits if cost structure is managed.

Low Leverage And Minimal DebtHaving little-to-no debt reduces near-term refinancing and interest risks, giving management optionality to pursue commercialization or partnerships without immediate creditor pressure. This structural conservatism preserves flexibility while the company scales assays and devices.

Bears Say

Sustained Negative Cash FlowPersistent -£5.1m operating and free cash flow indicates the business cannot self-fund growth and needs external capital within months. Continued cash burn constrains R&D, commercial expansion and increases dilution or financing risk, limiting durable financial resilience.

Ongoing Operating LossesConsistent ~£5m annual losses show the cost base outpaces current revenue scale. Without margin improvement or substantial revenue acceleration, losses will persist, preventing self-sustaining operations and pressuring the balance sheet and investor support over the medium term.

Compressed Equity And Balance Sheet StressShrinking shareholders' equity to ~£1.4m reduces the capital cushion and makes the company vulnerable to further losses. Historical balance-sheet stress (including past negative equity) raises the probability of future dilution or urgent fundraising, limiting strategic flexibility.

Genedrive News

Genedrive shareholders back fundraising as company expands pharmacogenetic footprint

The latest update is out from Genedrive ( ($GB:GDR) ). Genedrive plc, a Manchester‑based pharmacogenetic testing specialist, develops...

7d ago

Genedrive Raises £5.26 Million to Bolster Point-of-Care Pharmacogenetics Push

An update from Genedrive ( ($GB:GDR) ) is now available. Genedrive plc, a UK-listed point-of-care pharmacogenetic testing specialist,...

7d ago

Genedrive completes £500,000 placing as part of wider AIM fundraising

The latest update is out from Genedrive ( ($GB:GDR) ). Genedrive has completed a placing of 50,000,000 new...

1M ago

Genedrive launches £5.5m fundraise to drive pharmacogenetic growth

Genedrive ( ($GB:GDR) ) has shared an announcement. Genedrive plc plans to raise up to £5.5 million through...

1M ago

Genedrive Wins Major Shareholder Backing for Up to £6m Equity Raise to Fund Growth

The latest announcement is out from Genedrive ( ($GB:GDR) ). Genedrive plc has secured strong indicated backing from...

2M ago

Genedrive Wins Shareholder Backing for All AGM Resolutions

Genedrive ( ($GB:GDR) ) has issued an announcement. Genedrive plc, a UK-based specialist in point-of-care pharmacogenetic testing for...

2M ago

Genedrive’s CYP2C19 ID Kit Piloted in Scottish NHS for Stroke Care Innovation

Genedrive ( ($GB:GDR) ) has issued an announcement. Genedrive PLC announced the initiation of a ‘test of change’...

3M ago

Genedrive Launches Interactive Investor Hub to Enhance Stakeholder Engagement

The latest update is out from Genedrive ( ($GB:GDR) ). Genedrive plc has launched an interactive investor hub...

3M ago

Genedrive Secures £1 Million Shareholder Loan to Support Strategic Goals

Genedrive ( ($GB:GDR) ) has provided an announcement. Genedrive plc has secured a shareholder loan agreement with David...

3M ago

Genedrive plc Releases 2025 Annual Report and Sets AGM Date

The latest announcement is out from Genedrive ( ($GB:GDR) ). Genedrive plc has released its 2025 Annual Report...

3M ago

GDR FAQ

What was Genedrive PLC’s price range in the past 12 months?

Genedrive PLC lowest share price was 0.19 p and its highest was 2.17 p in the past 12 months.

What is Genedrive PLC’s market cap?

Genedrive PLC’s market cap is £16.86M.

When is Genedrive PLC’s upcoming earnings report date?

Genedrive PLC’s upcoming earnings report date is Mar 26, 2026 which is in 10 days.

How were Genedrive PLC’s earnings last quarter?

Genedrive PLC released its earnings results on Dec 05, 2025. The company reported -0.005 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.005 p.

Is Genedrive PLC overvalued?

According to Wall Street analysts Genedrive PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Genedrive PLC pay dividends?

Genedrive PLC does not currently pay dividends.

What is Genedrive PLC’s EPS estimate?

Genedrive PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genedrive PLC have?

Genedrive PLC has 1,605,568,200 shares outstanding.

What happened to Genedrive PLC’s price movement after its last earnings report?

Genedrive PLC reported an EPS of -0.005 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.596%.

Which hedge fund is a major shareholder of Genedrive PLC?

Currently, no hedge funds are holding shares in GB:GDR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genedrive PLC

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.